Assuntos
Adalimumab , Síndrome de Behçet , Hidradenite , Humanos , Adalimumab/uso terapêutico , Adalimumab/efeitos adversos , Síndrome de Behçet/tratamento farmacológico , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/complicações , Hidradenite/induzido quimicamente , Hidradenite/tratamento farmacológico , Hidradenite/patologia , Masculino , Anti-Inflamatórios/uso terapêutico , Adulto , Feminino , Neutrófilos/patologiaRESUMO
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans and has the potential to progress locally, metastasize, and cause death in a subset of patients. cSCC is especially common in the elderly, and it will probably represent a major health concern in the near future. Surgery is the standard treatment for cSCC, but intralesional therapies can sometimes be considered for certain patients and under certain circumstances. The choice of intralesional treatment depends on the patient's characteristics and the clinician's previous experience and expertise. Here we are reviewing intralesional treatments for cSCC and keratoacanthoma (KA). We have started with some classic drugs, such as methotrexate and 5-fluorouracil, bleomycin, interferon, and cryosurgery, but also comment on electrochemotherapy. Finally, we have focused on novel therapies, some of which are under development, and future perspectives, including intralesional immunotherapy and oncolytic viruses.